SerpApi.Org
Thousands of veterans diagnosed with prostate cancer could gain access to expanded specialized treatment and cutting-edge clinical trials under newly introduced legislation.
The Precision Oncology Program for Cancer of the Prostate (POPCaP) Authorization Act would permanently authorize and expand the Department of Veterans Affairs‘ precision oncology program.
The bill, introduced by Senate Veterans’ Affairs Committee Chairman Jerry Moran, would also create seven new Centers of Excellence dedicated to prostate cancer care within the VA health system.
“There must be adequate research, resources, and outreach available to veterans battling cancer,” Moran, a Kansas Republican, said in a statement. “This bill will make certain that veterans with prostate cancer in rural America receive the same cutting-edge therapies as a veteran living next to a major urban research hospital and have all the support they need, and deserve, to recover.”
Why It Matters
Prostate cancer is the most commonly diagnosed cancer among U.S. veterans, with the Department of Veterans Affairs (VA) diagnosing roughly 15,000 veterans with the disease each year.
Veterans are also twice as likely to be diagnosed with prostate cancer as their civilian counterparts, making specialized treatment a major issue for the VA healthcare system.
What to Know
On Monday, Moran introduced the Precision Oncology Program for Cancer of the Prostate (POPCaP) Authorization Act, which would permanently authorize and expand the VA’s current precision oncology program for veterans with prostate cancer.
According to Moran’s office, the bill would create seven new Centers of Excellence at VA medical centers across the country while establishing a performance-review process intended to maintain quality standards.
The proposal builds on an existing network of 21 POPCaP/Genitourinary Centers of Excellence that already provide veterans with advanced prostate cancer care, genetic testing and access to clinical trials.
The bill’s ask for $15 million has some concerned about how well the VA’s prostate cancer centers could actually be funded.
“Compared to most cancer research funding, $15.5 million is a very small amount, especially when it’s meant to support research across 21 facilities. I commend the intent behind the bill. Anything that takes aim at an issue affecting our veterans is worthwhile,” Kevin Thompson, the CEO of 9i Capital Group and the host of the 9innings podcast, told Newsweek. “My concern is that the funding simply doesn’t match the scope of the problem.”
How Veterans Would Benefit
The POPCaP program focuses on precision oncology, a special approach that uses a patient’s genetic information and the genetic makeup of a tumor to help physicians tailor treatments to the individual veteran rather than solely relying on standard treatment protocols.
Under the VA program, veterans may receive:
- Advanced genetic testing
- Genetic counseling
- Access to targeted therapies
- Enrollment opportunities in clinical trials
- Personalized treatment plans based on tumor genetics
Expanding the program could be particularly important for veterans who live far from major research hospitals.
“Because the price tag is relatively small, I think the bill has a reasonable chance of making it through the legislative process,” Thompson said. “The bigger question is whether it will meaningfully improve outcomes for veterans or simply provide a political victory that lawmakers can point to back home.”
How Many Veterans Are Affected?
According to the VA, prostate cancer accounts for roughly 30 percent of all new cancer diagnoses within the VA healthcare system, and roughly 15,000 veterans are diagnosed each year.
Certain groups face particularly elevated risks.
While in general veterans face disproportionately higher risk from service-related exposures, Black veterans experience about twice the diagnosis rate and twice the mortality rate compared with other groups., according to ZERO Prostate Cancer.
“Veterans face increased health risks from military environmental and toxic exposures, including asbestos, solvents, chemicals, and burn pits. Exposure to a multitude of carcinogenic toxins contributes to higher rates of critical diagnoses like prostate cancer and asbestos-related diseases,” Aaron Munz, director of the Veterans Department at the Mesothelioma Center at Asbestos.com, told Newsweek.
“This bill helps address disparities in access to care for the most common cancer in veterans. Providing early detection and world-class treatment options can dramatically improve outcomes for veterans.”
Where Would the New Centers Be?
The bill calls for the creation of seven additional Centers of Excellence, it’s not yet clear which VA medical centers would receive the new designations.
Currently, there are 21 POPCaP/Genitourinary Centers of Excellence operating within the VA system.
“If this becomes law, the long-term value isn’t a bigger disability check or a new compensation program,” Michael Ryan, a finance expert and the founder of MichaelRyanMoney.com, told Newsweek.
“It’s that vets with prostate cancer would have more consistent access to specialized treatment, precision medicine, and genetic testing through a program that’s no longer dependent on changing priorities from one administration or budget cycle to the next.”
What Happens Next
The Senate bill has entered the early stages of the legislative process. It will be considered by congressional committees before lawmakers decide whether to advance it for votes in the House and Senate.
“By permanently authorizing the VA’s precision oncology program, this legislation could give more veterans access to personalized treatments that could ultimately lead to earlier intervention and more targeted therapies,” Alex Beene, a financial literacy instructor for the University of Tennessee at Martin, told Newsweek.
“Its passing is absolutely possible given its focus on expanding an existing program which has historically enjoyed support across party lines.”
Contact Newsweek editors on this story: Jason Lemon and Dave Siminoff.
Related Articles
